|
Synonyms: JJP-1212 | JJP1212
Compound class:
Antibody
Comment: Nebaprubart (JJP-1212) is a potential first-in-class monoclonal antibody that targets Fc alpha receptor (FCAR; CD89).
Peptide sequence matches for the heavy and light chains of nebaprubart are claimed in patent US20230242646 [1]. In this patent, the most likely candidate to be nebaprubart is clone 10E7 humanized VL3 (VH3SQVL3). Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
| References |
|
1. Simons PJ, den Hartog MT, Boon L. (2023)
Humanized Anti-Human CD89 Antibodies and Uses Thereof. Patent number: US20230242646A1. Assignee: Polpharma Biologics Utrecht BV, JJP Biologics Sp zoo. Priority date: 21/04/2021. Publication date: 03/08/2023. |